Egypt will receive enough of Pfizer's Paxlovid pills to treat 20,000 patients, and enough of AstraZeneca's Evusheld antibodies to treat 50,000 patients from COVID-19.
By the end of January, 2022, the first shipments of Pfizer's Paxlovid pills and AstraZeneca's Evusheld antibodies will arrive in Egypt. Paxlovid is the first treatment of its kind to help patients who have contracted mild to moderate COVID-19, while Evusheld has been designed to help immunocompromised patients avoid contracting the virus. Paxlovid has reportedly been able to reduce the risk of hospitalisation or death by up to 89%, if taken during the early days of infection.
Egypt will receive enough Paxlovid pills to treat 20,000 patients, and enough Evusheld to treat 50,000 patients.
Additionally, three national companies in Egypt are manufacturing Merck's Molnupiravir drug, another pill to treat adults who have contracted mild to moderate COVID-19.